Skip to main content

Table 5 Total treatment costs for with and without SEB scenarios in year 2

From: A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada

Patient type (CKD stage) Treatments for anemia Year 2 total costs ($)
Without SEB With SEB
Stage III/IV Short acting ESA (SC) 31,736,891 25,402,208
Long acting ESA (SC) 33,013,420 26,423,942
Epoetin SEB - 4,040,419
Stage V Short acting ESA (SC) 26,456,982 21,176,169
Long acting ESA (SC) 18,321,156 14,664,254
Short acting ESA (IV) 108,692,464 86,997,449
Long acting ESA (IV) 75,583,082 60,496,699
Epoetin SEB - 14,292,950
Total 293,803,997 253,494,088
  1. SEB = subsequent entry biologic; CKD = chronic kidney disease; ESA = erythropoiesis stimulating agents; SC = subcutaneous; IV = intravenous.